Novo stops all development activities for once weekly victoza!

Wow, total failure, once weekly victoza doesn't work!

 

You are referring to Bye-dureon, that's the one that failed vs. Victoza. These are the news for Victory-za!




Novo Nordisk to start phase three semaglutide study
Reuters – 10 hours ago

COPENHAGEN (Reuters) - Denmark's Novo Nordisk, the world's biggest insulin producer, is initiating a phase three study of its once-weekly diabetes analogue semaglutide, the company said.
Novo Nordisk said in a statement late on Thursday the phase two development of semaglutide had been completed successfully in 2010 and followed by studies to compare it with a once-weekly formulation of liraglutide, the active ingredient in Novo Nordisk's diabetes treatment Victoza.
"These, now completed, phase 1 trials reconfirmed the safety profile of liraglutide," the company said in a statement, adding the studies had shown semaglutide had a more attractive profile for once-weekly administration.
"Consequently, Novo Nordisk has decided to focus on further development of semaglutide, while no further clinical activities with the once-weekly version of liraglutide are expected," the company said.
It plans to initiate the first phase three study in the program in the first half of 2013, it said.

 

You are referring to Bye-dureon, that's the one that failed vs. Victoza. These are the news for Victory-za!




Novo Nordisk to start phase three semaglutide study
Reuters – 10 hours ago

COPENHAGEN (Reuters) - Denmark's Novo Nordisk, the world's biggest insulin producer, is initiating a phase three study of its once-weekly diabetes analogue semaglutide, the company said.
Novo Nordisk said in a statement late on Thursday the phase two development of semaglutide had been completed successfully in 2010 and followed by studies to compare it with a once-weekly formulation of liraglutide, the active ingredient in Novo Nordisk's diabetes treatment Victoza.
"These, now completed, phase 1 trials reconfirmed the safety profile of liraglutide," the company said in a statement, adding the studies had shown semaglutide had a more attractive profile for once-weekly administration.
"Consequently, Novo Nordisk has decided to focus on further development of semaglutide, while no further clinical activities with the once-weekly version of liraglutide are expected," the company said.
It plans to initiate the first phase three study in the program in the first half of 2013, it said.

 

Better go check where your information is coming from!!!

 

"no further clinical activities with the once-weekly version of liraglutide are expected," the company said"

Let's see, all clinical development of lira once weekly are stopped because of an unattractive profile, and they refocus efforts on an unproven and higher risk molecule call semiglutide. No, that's doesn't sound like a failure for once weekly lira at all, lol

 

Very perceptive grasshopper. You see through the BS Spin job that Novo is famous for.

 

Well thank you, but it wasn't hard. I knew they were in trouble when the trolls started posting company press releases, lol, what a joke. Lira once weekly failed and now this backup contingency molecule semiglutide will also fail

 

Best part is semenglutide won't begin phase 3 trials until mid 2013. Study will take at least 1 yr to complete and compile, FDA won't even review for another year.

By then we'll have 30 percent of GLP1 market

 

Novo Nordisk (NVO - Snapshot Report) recently announced that it is planning to initiate a phase III global development program, SUSTAIN, for its type II diabetes candidate, semaglutide. Novo Nordisk expects to begin the first phase III study in this program in the first half of 2013. More than 8,000 patients are expected to be enrolled in the SUSTAIN studies.

Semaglutide is a once-weekly human glucagon-like peptide-1 (GLP-1) analogue. Before moving the candidate into late-stage studies, the company decided to conduct phase I trials comparing semaglutide with a once-weekly formulation of Victoza (liraglutide). This trial was conducted to assess and select the better candidate for phase III.

In the phase I trials, while once-weekly Victoza demonstrated a better safety profile, semaglutide was found to be more promising for once-weekly dosing. As a result, Novo Nordisk has decided to develop semaglutide further and harbors no plans to advance the once-weekly formulation of Victoza.

 

this is a Novo press release, not a third part assessment so you can save the spin. Bottom line is that the tried, tested and approved Liragllutide failed to meet once weekly dosing requirements for undisclosed reasons. so in an effort to save face and keep some kind of once weekly program in their pipeline Novo announces they are moving forward with some unproven, untested and likely to fail new compound. HA!

 

When Byetta came out, it was unproven. Look what happened to it when Victoza came out. When Victoza receives the weight loss indication, Bydureon will be second rate. When semaglutide hits the market, Novo's name will help launch it.

 

You are a fool. A once weekly candidate going into phase 3 now will when it is ready for market need to compete with the 2nd generation GLP-1's comming out and not Bydureon. No matter how you twist it Amylin will lose the battle either to Novo or some of the other competitors - as you must have noticed Bydureon has a hard time competing against the once daily Victoza.

 

you will not be competing with amylin but rather merck or sanofi or... good luck as the ultimately buyer of amylin kicks your buttt and your unproven and untested semiglutid fails in the clinic

 

Lilly will be the winner, bet your bottom depends.

 

So what you are saying is that Bydureon is not selling because you are an Amylin rep, but once that it has been passed to a real "Sanofi" or "Merck" rep it would be a complete success. You see, we agreed on something, I also think that the flat numbers are due to the salesforce, NOT the drug, buyout will be Bydureon's salvation but your suicide.

Then you see the nerve of some reps saying that the want the new company to keep them. Why would a company keep a salesforce that proved to be a failure?

 

So what you are saying is that Bydureon is not selling because you are an Amylin rep, but once that it has been passed to a real "Sanofi" or "Merck" rep it would be a complete success. You see, we agreed on something, I also think that the flat numbers are due to the salesforce, NOT the drug, buyout will be Bydureon's salvation but your suicide.

Then you see the nerve of some reps saying that the want the new company to keep them. Why would a company keep a salesforce that proved to be a failure?

 

Regardless of whether they keep us or not, and that's debatable, you'll be facing a company with deep pockets that can and will properly resource the marketing and sales teams. Let's see how you do when Bydureon is in the hands of a few thousand well funded reps vs the several hundred we have now.

 

I would put my money on ANY Amylin Legacy rep versus the Novo sales force head to head. That's why Novo is phone screening and interviewing our reps and managers now. Yeah we stink alright!!!

 

Maybe, but several very large companies have tried cracking the diabetes market and have fallen spectacularly on their faces. Pfizer the most obvious case, the only recent product to have done well in diabetes using the "Big Pharma" approach has been Januvia. 99% of its success is the simple fact it is a tablet not an injection.

 

and in the right hands 99% of the reason bydureon will crush vickytozy will be because it's easier once a week, ha ha!